Close Menu
Home › Novartis Seeks FDA OK for Drug With Favorable Phase III Results in PIK3CA-Mutated Breast Cancer

Novartis Seeks FDA OK for Drug With Favorable Phase III Results in PIK3CA-Mutated Breast Cancer

May 16, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Novartis has filed a new drug application with the US Food and Drug Administration for its investigational drug alpelisib — an alpha-specific PI3 kinase inhibitor that shows promise for treating hormone receptor-positive, HER2-negative advanced breast cancers with PIK3CA mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
03
Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Precision Oncology Specialties

  1. USPSTF Formalizes Slightly Expanded BRCA Screening Recommendations

  2. Lexent Bio Details Liquid Biopsy Monitoring Method, Expects Clinical Launch Next Year

    Premium

  3. New FDA Program May Help Oncologists Access Investigational Drugs in Precision Medicine Era

    Premium

  4. Xylonix, BioGemex Ink MOU to Develop Point-of-Care Cancer Immunotherapy-Response Diagnostic

  5. Liquid Biopsy Study Investigates Treatment for Breast Cancer Patients With Acquired HER2 Mutations

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.